arrow
J

Jennifer E. Klomp

University of North Carolina at Chapel Hill
H指数:20
被引数:2,382

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer

定义支持胰腺癌KRAS-和ERK依赖性生长的MYC调控转录组与激酶组

2025-09-300
PRE
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Science
IF45.8
2024-01-010
OA
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer
Science
IF45.8
2024-01-010
OA
TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

TEAD抑制克服了YAP1/TAZ驱动的对KRASG12C抑制剂的原发性和获得性抗性

2023-11-0718
OA
Determination of KRAS- and ERK-regulated phosphoproteomes in KRAS-mutant cancers
2023-05-010
PRE
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer

联合CDK4/6抑制剂治疗KRAS突变型胰腺癌

2022-11-0857
OA
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
2021-11-0121
OAAI
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment

CHK1保护致癌KRAS表达细胞免受DNA损伤,是胰腺癌治疗的靶点

2021-11-0123
OAAI
Targeting p130Cas-and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition

靶向p130Cas-and微管依赖的MYC调节使胰腺癌对ERK MAPK抑制敏感

2021-06-0118
OAAI
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer (vol 25, pg 628, 2019)

ERK和自噬抑制的组合作为胰腺癌的治疗方法 (第25卷,628页,2019)

2020-06-0117
OAAI
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer

非典型KRASG12R突变体在胰腺癌的PI3K信号传导和巨胞饮作用中受损

2020-01-09139
OAAI
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

ERK联合自噬抑制治疗胰腺癌的研究进展

2019-03-04526
OAAI